Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
For the treatment of pneumonia due to Pneumocystis carinii.
SUNY - Stony Brook, Stony Brook, New York, United States
University of Washington AIDS CRS, Seattle, Washington, United States
Bmc Actg Crs, Boston, Massachusetts, United States
Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States
Tulane Univ School of Medicine, New Orleans, Louisiana, United States
Charity Hosp / Tulane Univ Med School, New Orleans, Louisiana, United States
SUNY / State Univ of New York, Syracuse, New York, United States
Julio Arroyo, West Columbia, South Carolina, United States
Fisons Corp, Rochester, New York, United States
UCI Med Ctr, Orange, California, United States
Cedars Sinai Med Ctr, Los Angeles, California, United States
AIDS Community Research Consortium, Redwood City, California, United States
Northwestern Univ Med School, Chicago, Illinois, United States
Beth Israel Deaconess - West Campus, Boston, Massachusetts, United States
Georgetown Univ, Washington, District of Columbia, United States
Fisons Corp, Rochester, New York, United States
Fisons Corp, Rochester, New York, United States
LyphoMed Inc, Rosemont, Illinois, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.